Check-Cap (NASDAQ:CHEK) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEKFree Report) in a research report released on Monday morning. The brokerage issued a sell rating on the medical research company’s stock.

Check-Cap Trading Up 4.9 %

Shares of NASDAQ:CHEK opened at $1.29 on Monday. The stock has a market capitalization of $7.55 million, a P/E ratio of -0.43 and a beta of 0.17. Check-Cap has a 1-year low of $0.56 and a 1-year high of $3.45. The business has a 50-day moving average price of $1.02 and a two-hundred day moving average price of $1.44.

Check-Cap Company Profile

(Get Free Report)

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.

Featured Articles

Receive News & Ratings for Check-Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap and related companies with MarketBeat.com's FREE daily email newsletter.